Sachin Haresh Bhagchandani
he/him/his
Postdoctoral AssociateAbout
Research
Publications
2026
Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes.
Bhagchandani SH, Ehrenzeller S, Pires IS, Chaudhary N, Booth CJ, Kwon DI, Koutsioumpa C, Baker CA, Laxton C, Santos Guedes de Sá K, Matthews C, Gill P, Li S, Olszowka A, Hudak A, Fischer S, Bayarri-Olmos R, Hooper WB, Iwasaki A. Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes. Sci Immunol 2026, 11: eaea6419. PMID: 42319912, DOI: 10.1126/sciimmunol.aea6419.Peer-Reviewed Original ResearchThis study investigates a novel vaccine strategy using BEACONs, a mucosal adjuvant, to enhance localized immunity and protect against genital herpes by boosting tissue-resident T cells and antibodies.A causal link between autoantibodies and neurological symptoms in long COVID
de Sá K, Silva J, Bayarri-Olmos R, Baker C, Lu Z, Gipson W, Na D, Chen B, Wenxue L, Khosroabadi D, Brinda R, Constable R, Omene B, Colom Díaz P, Kwon D, Rodrigues G, Heidecke H, Schulze-Forster K, Gross A, Shneer T, Clarke A, Linnekin T, Brate A, Brown L, Buda H, Jatiani S, Moise L, Greene K, Bhagchandani S, Bhattacharjee B, Gehlhausen J, Wood J, Tabacof L, Scheibenbogen C, Liu Y, Guan L, Schneeberger Pane M, Putrino D, Horvath T, Iwasaki A. A causal link between autoantibodies and neurological symptoms in long COVID. Cell 2026, 189: 3214-3235.e37. PMID: 42208499, DOI: 10.1016/j.cell.2026.04.042.Peer-Reviewed Original ResearchConceptscentral nervous systemneurological symptomspatient's symptomspain-related neuronal activitypassive transferacute SARS-CoV-2 infectionantibody-dependent phagocytosistissue-based immunofluorescenceSARS-CoV-2 infectionpurified immunoglobulin Ghuman locus coeruleusthermal hyperalgesiafunctional autoantibodiesfatigue-like behaviormass spectrometry assaymouse sciatic nervetransfer of IgGadrenal glandnerve damagelocus coeruleuspathogenic roleautoantibodiespassive transfer of IgGsciatic nerveautoantibody targetsHarnessing mucosal immunity for protective vaccines
Kwon D, Bhagchandani S, Ehrenzeller S, Iwasaki A. Harnessing mucosal immunity for protective vaccines. Nature Reviews Immunology 2026, 26: 507-524. PMID: 41699393, PMCID: PMC13088808, DOI: 10.1038/s41577-026-01273-7.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statementsmucosal immunitytissue-resident memory Tlocal antibody secretionpathogen-specific immune responseseffective mucosal immunitycomplex immune environmentmemory Timmune environmentmucosal sitesmucosal vaccinesmucosal compartmentsB cellsepithelial barriereffector mechanismssterilizing immunityantibody secretionprotective immunityimmune responsemucosal surfaceshormonal influencesparenteral vaccinationeffective vaccineimmunityvaccineinfectious pathogens
2025
Antibody–bottlebrush prodrug conjugates for targeted cancer therapy
Liu B, Nguyen H, Jiang Y, Wang A, Lensch V, Sun Z, Boyer Z, Raftopoulos P, Dai Y, MacNicol P, Wang Y, Jyotsana N, Wang W, Bhagchandani S, Hemdev S, Shieh P, Kristufek S, Boucher M, Downes M, Evans R, MacMillan D, Johnson J. Antibody–bottlebrush prodrug conjugates for targeted cancer therapy. Nature Biotechnology 2025, 44: 1011-1022. PMID: 40925997, PMCID: PMC12425459, DOI: 10.1038/s41587-025-02772-z.Peer-Reviewed Original Researchantibody-drug conjugatesprodrug conjugatesHER2-targeting antibody-drug conjugatedrug mechanismstargeted cancer therapydrug-to-antibody ratiodrug mechanism of actionIgG1 monoclonal antibodymechanism of actiontumor modelcancer therapytargeted therapeuticsclinical translationmonoclonal antibodiesTraditional antibody-drug conjugatecell uptaketarget engagementA mechanically resilient soft hydrogel improves drug delivery for treating post-traumatic osteoarthritis in physically active joints
Joshi N, Yan J, Dang M, Slaughter K, Wang Y, Wu D, Ung T, Bhingaradiya N, Pandya V, Chen M, Kaur S, Bhagchandani S, Alfassam H, Joseph J, Gao J, Dewani M, Chu R, Yip R, Weldon E, Shah P, Pisal N, Shukla C, Sherman N, Luo J, Conway T, Eickhoff J, Botelho L, Alhasan A, Karp J, Ermann J. A mechanically resilient soft hydrogel improves drug delivery for treating post-traumatic osteoarthritis in physically active joints. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2409729122. PMID: 40163719, PMCID: PMC12002200, DOI: 10.1073/pnas.2409729122.Peer-Reviewed Original ResearchConceptstreat post-traumatic osteoarthritismechanical loadingsoft hydrogelsdrug releasekinetics of drug releaseintra-articular drug deliverypost-traumatic osteoarthritishydrogel potentialintra-articular deliverysoft materialshydrogelsdrug deliveryreduced cartilage degenerationSelf-Healingmouse knee jointsrelease kineticscartilage degenerationactive jointsloadsuperior performancestructural integrityencapsulated drugjointsdisease-modifying osteoarthritis drugsknee joint
2024
Two-dose priming immunization amplifies humoral immunity by synchronizing vaccine delivery with the germinal center response
Bhagchandani S, Yang L, Lam J, Maiorino L, Ben-Akiva E, Rodrigues K, Romanov A, Suh H, Aung A, Wu S, Wadhera A, Chakraborty A, Irvine D. Two-dose priming immunization amplifies humoral immunity by synchronizing vaccine delivery with the germinal center response. Science Immunology 2024, 9: eadl3755-eadl3755. PMID: 39303017, PMCID: PMC11492009, DOI: 10.1126/sciimmunol.adl3755.Peer-Reviewed Original ResearchConceptsdendritic cellsgerminal centershumoral immunityantigen-specific germinal centergerminal center responsesubunit vaccinefollicular dendritic cellsprimary immune responseincreased T<sub>rdose 7 daysprime immunizationGC responseimmune responsevaccine deliverycenter responseadministered vaccinesimmunityvaccineregimensadjuvant vaccinedosecellsHIVresponsebolusCarbohydrate-Lectin Interactions Reprogram Dendritic Cells to Promote Type 1 Anti-Tumor Immunity
Lensch V, Gabba A, Hincapie R, Bhagchandani S, Basak A, Alam M, Noble J, Irvine D, Shalek A, Johnson J, Finn M, Kiessling L. Carbohydrate-Lectin Interactions Reprogram Dendritic Cells to Promote Type 1 Anti-Tumor Immunity. ACS Nano 2024, 18: 26770-26783. PMID: 39283240, PMCID: PMC11646345, DOI: 10.1021/acsnano.4c07360.Peer-Reviewed Original Researchcellular immunitydendritic cellsToll-like receptorsvirus-like particlesCD8<sup>+</sup> T cellstumor-specific cellular immunityvaccine developmentcancer vaccine developmentinfiltrate solid tumorsmurine melanoma modelT cell functioninhibited tumor growthactivate TLR signalingtumor controlcancer immunotherapyCD4<sup>+</sup>melanoma modelTLR7 agonistDC activationT cellssolid tumorstumor cellstumor growthhumoral immunityVLP platform
2023
Mixing ligands to enhance gas uptake in polyMOFs
Pearson M, Bhagchandani S, Dincă M, Johnson J. Mixing ligands to enhance gas uptake in polyMOFs. Molecular Systems Design & Engineering 2023, 8: 591-597. DOI: 10.1039/d2me00227b.Peer-Reviewed Original Researchpolymer ligandsCO 2 uptaketunable surface areasurface areamixed ligand approachsmall molecule componentsdistinct MOFspolymeric ligandMOF latticeorganic frameworkspolymer linkerstraditional MOFspolyMOFshybrid materialsfree linkersMOF-5polymer incorporationligand approachgas uptakeMOFmolecule componentsligandslinkercomplex architectureHereinEngineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation
Bhagchandani S, Vohidov F, Milling L, Tong E, Brown C, Ramseier M, Liu B, Fessenden T, Nguyen H, Kiel G, Won L, Langer R, Spranger S, Shalek A, Irvine D, Johnson J. Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation. Science Advances 2023, 9: eadg2239. PMID: 37075115, PMCID: PMC10115420, DOI: 10.1126/sciadv.adg2239.Peer-Reviewed Original ResearchConceptsToll-like receptor 7cancer immunotherapyimmune stimulationmouse syngeneic tumor modelsnext-generation cancer immunotherapyimmune-related toxicitiesacute systemic inflammationinnate immune cellssyngeneic tumor modelspotential cancer immunotherapysystemic inflammationimmune cellsreceptor 7systemic administrationintravenous administrationmyeloid cellstumor growthsystemic toxicitytumor modelobservable systemic toxicitypotent stimulationimidazoquinolinesimmunotherapystimulationprodrugMolecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma
Detappe A, Nguyen H, Jiang Y, Agius M, Wang W, Mathieu C, Su N, Kristufek S, Lundberg D, Bhagchandani S, Ghobrial I, Ghoroghchian P, Johnson J. Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma. Nature Nanotechnology 2023, 18: 184-192. PMID: 36702954, PMCID: PMC10032145, DOI: 10.1038/s41565-022-01310-1.Peer-Reviewed Original ResearchConceptscombination therapymultiple myelomanarrow therapeutic indexmultiple myeloma therapyfree drug combinationfree drug counterpartsmyeloma therapysame dosetherapeutic indextumor progressionBPD exhibittherapyproteasome inhibitorscombination nanomedicinescancer therapymonotherapymyelomasynergistic ratio